• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • Cardiology, Diabetes & Nephrology – USA
    • Hatter Horizon Series
    • The 18th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Oncology
    • Cell Therapy at the Limits 2020
    • UCL Frontiers of Oncology 2019
      • Haematology
      • Melanoma
      • Urology
      • Women’s Health
      • Lung Cancer
      • Gastrointestinal Oncology
      • Paediatric Oncology
      • Supporters
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
        • Introduction
        • Programme
        • Chairs
        • Venue
        • Sponsor Packages
        • Supporters
      • Oncology at the Limits 2017
        • Introduction
        • Chairs
        • Programme
        • Schedule
        • Venue
        • Hotel
        • Information
        • Supporters
        • OATL 2017: Login
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Previous Events
      • Multiple Sclerosis Nurses at the Limits 2019
        • Introduction
        • Express Interest in MSNATL 2020
        • Programme
        • Chairs
        • Venue
        • Hotel
        • Information
        • Conflict of Interest Forms
        • Supporters
      • MSATL 2018: Introduction
        • MSATL 2018: Programme
        • MSATL 2018: Chairs
        • MSATL 2018: Schedule
        • MSATL 2018: Venue
        • MSATL 2018: Hotel
        • MSATL 2018: Information
        • MSATL 2018: CME Accreditation
        • MSATL 2018: Supporters
        • MSATL 2018: Conflict of Interest Forms
      • MSATL 2017: Introduction
        • MSATL 2017: Chairs
        • MSATL 2017: Schedule
        • MSATL 2017: Programme
        • MSATL 2017: Venue
        • MSATL 2017: Supporters
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Register Interest
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series 2018
    • Multiple Sclerosis at the Limits 2018
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Hatter Horizon Series 2017
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017
  • Supporters

Dr Alan Ashworth

Alan Ashworth, Ph.D., F.R.S., is currently President of the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, a role he began in January 2015.  He was previously Chief Executive of the Institute of Cancer Research (ICR) in London, United Kingdom.

In 1999 he was appointed the first Director of the Breakthrough Breast Cancer Research Centre where he was also Professor of Molecular Biology and leader of the Gene Function team.  Professor Ashworth’s Directorship ended in January 2011 when was appointed Chief Executive of the ICR.

A translational biologist and laboratory researcher, Dr. Ashworth’s research focuses on understanding breast cancer genetics and applying what he learns to change the way patients are treated. He was a key part of the team that identified the BRCA2 breast cancer susceptibility gene, which is linked to an increased risk of some types of cancer.  Ten years later, Dr. Ashworth found a way to kill BRCA1- and 2-related tumor cells by treating them with PARP inhibitors, which amplifies the damage caused by the broken DNA repair machinery in those cells. This exemplifies the genetic principle of synthetic lethality in cancer therapy.

Dr. Ashworth is an elected member of EMBO and the Academy of Medical Sciences and a Fellow of the Royal Society. He has been the recipient of a number of scientific prizes and awards including The European Society of Medical Oncology Lifetime Achievement Award, the David T. Workman Memorial Award of the Samuel Waxman Cancer Research Foundation and the Meyenburg Foundation’s Cancer Research Award and was the inaugural winner of the 2013 Basser Global Prize. He has also recently been selected as the recipient of the 2015 Genetics Society Medal.

« Professor Mark Lemmon
Professor Bart Vanhaesebroeck »

Hatter Horizon GP Meeting
Tuesday, 3 December 2019
London, UK

Hatter Horizon Series
Monday, 9 December 2019
London, UK

Multiple Sclerosis Nurses at the Limits
Friday, 10 & Saturday, 11 January 2020, London, UK

Multiple Sclerosis at the Limits
Thursday, 23 & Friday, 24 January 2020, London, UK

Frontiers of Oncology: Colorectal Cancer
February 2020, London, UK

Cardiology, Diabetes & Nephrology at the Limits 2020
Monday, 20 - Wednesday, 22 April 2020, London, UK

Cell Therapy at the Limits 2020
Thursday, 21 - Friday, 22 May 2020, London, UK

The 18th Malvern Diabetic Foot Conference
Wednesday, 13 - Friday, 15 May 2020, Malvern, UK

Cardiology, Diabetes & Nephrology at the Limits Brazil
Friday, 17 - Saturday, 18 July 2020, São Paulo, Brazil

Cardiology, Diabetes & Nephrology at the Limits Canada
Monday, 4 - Tuesday, 5 May 2020, Toronto, Canada

  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
  • Medical Disclaimer
  • Disclosure
  • E-mail Policy
  • Privacy Policy
  • Anti-spam Policy
  • Disclaimer
  • External Links Policy
  • Terms of use
  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2019 At the Limits Ltd.
This site uses cookies More info